TP53 and B-cell chronic lymphocytic leukemia: Since several decades, we have used prognostic and predictive genetic biomarkers such as FISH-based detection of recurrent chromosomal aberrations and sequenced-based assessment of the TP53 and IGHV SHM status in the clinical management of CLL.